Akari Therapeutics Eyes Next-Gen ADC Opportunity with Whitehawk Collaboration
Event summary
- Akari CEO Abizer Gaslightwala discussed strategic collaboration with Whitehawk Therapeutics in a Virtual Investor interview on July 22, 2026.
- The partnership aims to evaluate Akari's PH1 spliceosome-modulating payload combined with Whitehawk's TOP1i ADC platform in preclinical studies.
- Akari highlights growing industry demand for differentiated ADC payload technologies as a key strategic opportunity.
The big picture
Akari Therapeutics is positioning itself as a key player in the next wave of ADC innovation by leveraging its proprietary PH1 payload technology. The collaboration with Whitehawk underscores the industry's shift toward differentiated payload approaches, potentially expanding therapeutic opportunities beyond traditional single-payload ADCs.
What we're watching
- Payload Innovation
- How Akari's PH1 spliceosome-modulating payload will differentiate in the competitive ADC landscape.
- Collaboration Outcomes
- Whether preclinical data from the Whitehawk partnership validates dual-payload synergy for next-gen ADCs.
- Regulatory Timeline
- The pace at which Akari advances AKTX-101 toward its First-In-Human trial, targeting mid-2027.
Related topics